These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 24369278

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H, Hamaya E, Yamamoto T.
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
    Nakamura Y.
    Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
    Yamamoto T, Hamaya E, Sowa H.
    Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
    [Abstract] [Full Text] [Related]

  • 10. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
    Marumo K, Saito M.
    Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.
    Chen JF, Yang KH, Zhang ZL, Chang HC, Chen Y, Sowa H, Gürbüz S.
    Osteoporos Int; 2015 Jan; 26(1):11-28. PubMed ID: 25138261
    [Abstract] [Full Text] [Related]

  • 15. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A.
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [Abstract] [Full Text] [Related]

  • 16. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.
    Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Ozawa T, Takahashi K, Toyone T.
    Spine (Phila Pa 1976); 2012 Nov 01; 37(23):E1464-8. PubMed ID: 22872218
    [Abstract] [Full Text] [Related]

  • 17. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T.
    Curr Med Res Opin; 2013 Mar 01; 29(3):195-203. PubMed ID: 23259702
    [Abstract] [Full Text] [Related]

  • 18. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.
    Stroup JS, Rivers SM, Abu-Baker AM, Kane MP.
    Pharmacotherapy; 2007 Jun 01; 27(6):779-88. PubMed ID: 17542760
    [Abstract] [Full Text] [Related]

  • 19. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep 01; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 20. [Therapeutic agents for disorders of bone and calcium metabolism: Weekly subcutaneous injection of teriparatide.].
    Ishizuya T.
    Clin Calcium; 2011 Jan 01; 21(1):17-24. PubMed ID: 21187590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.